All In Biotech

Drug Trial Radar · NCT02727751

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

An Open Label Long-Term Safety Study of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

312

Actual

Start

Mar 2016

Primary completion

Oct 2017

Study completion Oct 2017

Sponsor

Lead sponsor
ArdelyxIndustry
Sponsor type
Industry
First posted
Apr 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria. Subjects who have completed either TEN-01-301 (16 weeks) or TEN-01-302 (26 weeks) studies may be enrolled. Subjects will take tenapanor for approximately 52-55 weeks total based on previous protocol and this study.

Conditions

  • Constipation Predominant Irritable Bowel Syndrome

Interventions

  • TenapanorDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events in >2% PatientsTime frame: 52-55 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ardelyx Clinical Site

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.